Skip to main content

Advertisement

Table 1 Efficacy and adherence rates across PrEP trials

From: Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?

Study [reference]: countries Population n Efficacy Lower bound of 95% CI Adherencea
Partners PrEP [8]: Kenya, Uganda Heterosexual couples 4758 67% TDF; 75% TDF/FTC 44% TDF; 55% TDF/FTC 82%
TDF2 Study [9]: Botswana Young men and women 1219 62% TDF/FTC 21.5% 80%
Bangkok TDF [12]: Thailand IVDU 2413 49% TDF 9.6% 67%
iPrEx [7]: S. America, SA, Thailand, USA MSM 2499 44% TDF/FTC 15% 51%
FEM-PrEP [10]: Kenya, SA, Tanzania Young women 2120 6% TDF/FTC −52% 37%
VOICE [11]: South Africa, Uganda, Zimbabwe Young women 5029 −49% TDF; - 4% TDF/FTC −130% TDF; −50% TDF/FTC 30%
  1. Abbreviations: FTC, emtricitabine; IVDU, intravenous drug users; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; SA, South Africa; TDF, tenofovir disoproxil fumarate.
  2. aAdherence was assessed by the proportion of participants with drugs detectable in plasma and who remained free of infection in the active PrEP arms.